Vizsgálati helyszín
Sudarshan K Sharma MD Limited-Gynecologic Oncology
Hinsdale, Illinois 60521, Egyesült ÁllamokMég nincs intézményhez kötve
- 13futó vizsgálat
- 5lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 18 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 2. fázis7 vizsgálat
- 3. fázis7 vizsgálat
- 2/3. fázis3 vizsgálat
- Állapot
- Fut, nem toboroz13 vizsgálat
- Lezárult5 vizsgálat
- Fő szponzor
- National Cancer Institute (NCI)15 vizsgálat
- NRG Oncology2 vizsgálat
- GOG Foundation1 vizsgálat
Futó vizsgálatok
Fut, nem toboroz
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
NCT05256225· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
NCT04739800· 2. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NCT04251052· NRG Oncology· Forrás
Fut, nem toboroz
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT04095364· 3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer
NCT03348631· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
NCT03660826· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02839707· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
NCT02502266· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02446600· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
NCT02257528· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
NCT01081262· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
NCT00977574· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00565851· 3. fázis· National Cancer Institute (NCI)· Forrás
Hibát jelzek